Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck, Ranbaxy Team For Anti-Infectives
May 19, 2008
| A version of this story appeared in
Volume 86, Issue 20
Merck & Co. and Ranbaxy Laboratories of India, have entered into a five-year pact to develop anti-infective drugs. Initial fees were not disclosed, but the companies say Ranbaxy could earn more than $100 million in milestone payments as well as royalties on each drug that reaches commercialization. Ranbaxy will discover and develop compounds through early Phase II trials, at which point Merck will shepherd the drugs to market. The deal marks Merck's second major drug development pact with an Indian drug company. Last year, Merck signed on with Nicholas Piramal to develop oncology drugs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X